HomeCompareCLPBF vs QYLD

CLPBF vs QYLD: Dividend Comparison 2026

CLPBF yields 5.35% · QYLD yields 11.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CLPBF wins by $70.3K in total portfolio value
10 years
CLPBF
CLPBF
● Live price
5.35%
Share price
$66.48
Annual div
$3.56
5Y div CAGR
29.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$95.7K
Annual income
$25,092.03
Full CLPBF calculator →
QYLD
Global X Nasdaq 100 Covered Call ETF
● Live price
11.92%
Share price
$17.15
Annual div
$2.04
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$5,659.31
Full QYLD calculator →

Portfolio growth — CLPBF vs QYLD

📍 CLPBF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCLPBFQYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CLPBF + QYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CLPBF pays
QYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CLPBF
Annual income on $10K today (after 15% tax)
$454.79/yr
After 10yr DRIP, annual income (after tax)
$21,328.23/yr
QYLD
Annual income on $10K today (after 15% tax)
$1,013.51/yr
After 10yr DRIP, annual income (after tax)
$4,810.41/yr
At 15% tax rate, CLPBF beats the other by $16,517.81/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CLPBF + QYLD for your $10,000?

CLPBF: 50%QYLD: 50%
100% QYLD50/50100% CLPBF
Portfolio after 10yr
$60.6K
Annual income
$15,375.67/yr
Blended yield
25.39%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CLPBF right now

CLPBF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
3.1
Piotroski
7/9
QYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CLPBF buys
0
QYLD buys
1
PoliticianChamberTickerTypeAmountDate
Tim Moore🏢 House$QYLD▼ Sell$15,001 - $50,0002025-05-02
Tim Moore🏢 House$QYLD▲ Buy$15,001 - $50,0002025-04-07
Dwight Evans🏢 House$QYLD▼ Sell$1,001 - $15,0002022-11-14
Dwight Evans🏢 House$QYLD▼ Sell$1,001 - $15,0002020-10-29
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCLPBFQYLD
Forward yield5.35%11.92%
Annual dividend / share$3.56$2.04
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR29.3%0%
Portfolio after 10y$95.7K$25.4K
Annual income after 10y$25,092.03$5,659.31
Total dividends collected$67.0K$27.1K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: CLPBF vs QYLD ($10,000, DRIP)

YearCLPBF PortfolioCLPBF Income/yrQYLD PortfolioQYLD Income/yrGap
1← crossover$11,392$691.82$10,352$1,192.36+$1.0KCLPBF
2$13,142$952.36$10,830$1,347.57+$2.3KCLPBF
3$15,389$1,327.61$11,460$1,539.07+$3.9KCLPBF
4$18,345$1,878.66$12,275$1,777.84+$6.1KCLPBF
5$22,335$2,706.25$13,323$2,078.95+$9.0KCLPBF
6$27,881$3,981.62$14,667$2,463.34+$13.2KCLPBF
7$35,838$6,005.94$16,396$2,960.57+$19.4KCLPBF
8$47,676$9,329.10$18,631$3,612.97+$29.0KCLPBF
9$66,010$14,997.12$21,548$4,482.15+$44.5KCLPBF
10$95,723$25,092.03$25,398$5,659.31+$70.3KCLPBF

CLPBF vs QYLD: Complete Analysis 2026

CLPBFStock

Coloplast A/S develops and sells intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Interventional Urology, Voice and Respiratory Care, and Wound & Skin Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, hand cleanser, and odor control products, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, it offers voice and respiratory products, including medical devices for neck stoma under the Provox brand; and products for tracheostoma under the TRACOE brand. The company was founded in 1954 and is headquartered in Humlebæk, Denmark.

Full CLPBF Calculator →

QYLDETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →
📬

Get this CLPBF vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CLPBF vs SCHDCLPBF vs JEPICLPBF vs OCLPBF vs KOCLPBF vs MAINCLPBF vs XYLDCLPBF vs JEPQCLPBF vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.